352 related articles for article (PubMed ID: 21184269)
1. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
3. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
4. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
5. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Truong TH; Benner EA; Hagen KM; Temiz NA; Kerkvliet CP; Wang Y; Cortes-Sanchez E; Yang CH; Trousdell MC; Pengo T; Guillen KP; Welm BE; Dos Santos CO; Telang S; Lange CA; Ostrander JH
Oncogene; 2021 Jun; 40(25):4384-4397. PubMed ID: 34103681
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors and xenograft studies.
Chumsri S; Sabnis GJ; Howes T; Brodie AM
Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract][Full Text] [Related]
11. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
12. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
[TBL] [Abstract][Full Text] [Related]
15. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
16. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
17. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
18. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
19. Stopping treatment can reverse acquired resistance to letrozole.
Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]